-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, V+9TAa9usK4j9ZrLt8KGisj/3VYopOpU757gbNRzlDZqwAoFsvRiuErI2kE2T+9T mpcuzh58bQV07eOjJt4qPg== 0001096906-08-001089.txt : 20080528 0001096906-08-001089.hdr.sgml : 20080528 20080528080457 ACCESSION NUMBER: 0001096906-08-001089 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20080528 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20080528 DATE AS OF CHANGE: 20080528 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BSD MEDICAL CORP CENTRAL INDEX KEY: 0000320174 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 751590407 STATE OF INCORPORATION: DE FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32526 FILM NUMBER: 08862346 BUSINESS ADDRESS: STREET 1: 2188 W 2200 SOUTH CITY: SALT LAKE CITY STATE: UT ZIP: 84119 BUSINESS PHONE: 8019725555 MAIL ADDRESS: STREET 1: 2188 WEST STREET 2: 2200 SOUTH CITY: SALT LAKE CITY STATE: UT ZIP: 84119 8-K 1 bsdmedical8k052808.htm BSD MEDICAL CORPORATION FORM 8-K bsdmedical8k052808.htm

Washington, D.C.  20549


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 28, 2008

(Exact name of registrant as specified in its charter)

(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification)

2188 West 2200 South
Salt Lake City, Utah 84119
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code:  (801) 972-5555

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 7.01
Regulation FD Disclosure.

BSD Medical Corporation issued a press release on May 28, 2008.  A copy of the press release is hereby furnished as Exhibit 99.1 attached hereto.

Item 9.01.
Financial Statements and Exhibits.


Press Release of BSD Medical Corporation dated May 28, 2008


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:  May 28, 2008
/s/  Hyrum A. Mead               
Hyrum A. Mead



Exhibit No. Description99.1 Press Release of BSD Medical Corporation dated May 28, 2008

EX-99.1 2 bsdmedical8k052808ex99-1.htm BSD MEDICAL CORPORATION PRESS RELEASE bsdmedical8k052808ex99-1.htm

Exhibit 99.1

For Immediate Release
Phase III Clinical Study Using BSD Medical’s Systems for Treating Pancreatic Cancer to Be Announced at ASCO
SALT LAKE CITY—May 28, 2008— BSD Medical Corp. (NASDAQ:BSDM) announced today that a team of researchers headed by Professor Rolf D. Issels will be announcing at the upcoming annual American Society of Clinical Oncology (ASCO) conference that a Phase III clinical study is underway involving the combined use of hyperthermia therapy and chemotherapy in treating patients with pancreatic cancer.  This announcement follows the successful conclusion of a Phase II clinical trial conducted in Munich, Germany using a combination of hyperthermia therapy and chemotherapy to treat patients with pancreatic cancer.  All hyperthermia treatments used for this study will be delivered using BSD-2000 hyperthermia systems.  The ASCO conference held in Chicago, Illinois will run May 30 through June 3.

Pancreatic cancer is the fourth leading cause of cancer death in men and women.  The American Cancer Society has projected 37,170 new cases and 33,370 deaths from the disease in the United States this year.  While the use of hyperthermia therapy in treating some other forms of cancer has been heavily researched, little has been known about the potential of the therapy in treating pancreatic cancer patients, a deadly cancer for which better treatments are urgently needed.

ASCO is the world’s leading professional organization representing physicians who treat cancer.  More than 25,000 oncology practitioners belong to ASCO, from all oncology disciplines.  This clinical study being presented at ACRO is supported by the European Society for Hyperthermic Oncology (ESHO) and the Helmholtz Center Munich.



About BSD Medical Corporation

BSD Medical is a leading developer of systems used to provide cancer therapies requiring precision-focused heat through RF/microwave technologies. The company’s systems have been designed to kill cancer through heat alone, or as companion therapies to improve the combined results when used along with radiation treatments.  Application for marketing approval of the BSD-2000 mentioned in this press release has been filed with the FDA and is currently in the review process.  For further information visit BSD Medical's website at www.BSDMedical.com.


Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.